NERV

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Minerva Neurosciences Inc

NASDAQ | NERV

2.53

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 16, 2025)

$17.55M

Market Cap

1.696

P/E Ratio

1.48

EPS

$3.29

52 Week High

$1.14

52 Week Low

HEALTHCARE

Sector

NERV Chart

Recent Chart
Price Action

NERV Technicals

Tags:

NERV Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$22K
Total Revenue $0
Cost Of Revenue $22K
Costof Goods And Services Sold $22K
Operating Income -$22M
Selling General And Administrative $10M
Research And Development $12M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$4.6M
Interest Income -
Interest Expense $4.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $22K
Income Before Tax $1.4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $1.4M
Comprehensive Income Net Of Tax -
Ebit $6M
Ebitda $6M
Net Income $1.4M

Revenue & Profitability

Earnings Performance

NERV Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $37M
Total Current Assets $22M
Cash And Cash Equivalents At Carrying Value $21M
Cash And Short Term Investments $21M
Inventory -
Current Net Receivables -
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $15B
Intangible Assets Excluding Goodwill $15B
Goodwill $15M
Investments -
Long Term Investments -
Short Term Investments $100K
Other Current Assets $807K
Other Non Current Assets -
Total Liabilities $63M
Total Current Liabilities $2.8M
Current Accounts Payable $1.6M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $60B
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $60M
Other Current Liabilities $1.2M
Other Non Current Liabilities $60M
Total Shareholder Equity -$26B
Treasury Stock -
Retained Earnings -$395B
Common Stock $699
Common Stock Shares Outstanding $7.6M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$20M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $22K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $0
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $1.4M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$22K
Total Revenue $0
Cost Of Revenue $22K
Costof Goods And Services Sold $22K
Operating Income -$22M
Selling General And Administrative $10M
Research And Development $12M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$4.6M
Interest Income -
Interest Expense $4.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $22K
Income Before Tax $1.4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $1.4M
Comprehensive Income Net Of Tax -
Ebit $6M
Ebitda $6M
Net Income $1.4M

NERV News

NERV Profile

Minerva Neurosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in the development of innovative therapies for central nervous system disorders. The company’s robust pipeline targets significant unmet medical needs in neuropsychiatric conditions, emphasizing its commitment to research and development. By leveraging cutting-edge science, Minerva aims to transform treatment paradigms and improve quality of life for patients facing these challenging disorders. With its dedicated team and strategic focus, the company is well-positioned to make a meaningful impact in the field of neuroscience.

YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
AMD
+9.40%
$238.60
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
AAL
+2.54%
$12.50
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
WTO
-88.87%
$0.13
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
PLTR
-0.06%
$179.62
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
HIMS
-6.07%
$58.94
ORCL
+3.08%
$313.00
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
AMD
+9.40%
$238.60
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
AAL
+2.54%
$12.50
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
WTO
-88.87%
$0.13
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
PLTR
-0.06%
$179.62
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
HIMS
-6.07%
$58.94
ORCL
+3.08%
$313.00
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.